EBay and Amgen: Dividends do Matter

William Smead
Chief Executive Officer
Chief Investment Officer

Dear Fellow Investors:

We are owners of both EBay (EBAY) and Amgen (AMGN). We believe the dividend policy and price action in the shares of these two companies can teach us about stock price performance over the next three to five years.

History shows that for a few decades after terrible stock price performance (like we’ve seen from 1999 to 2011) investors demand more of their return from cash dividends because they do not trust appreciation. In the 1940’s and early 1950’s, investors demanded a higher cash dividend from stocks than they demanded from Treasury and Corporate Bonds. Treasuries yielded around 2% in 1950 and the Dow had around a 6% yield from dividends. However, in the aftermath of the 1929-32 crushing bear market in stocks and massive bank failures which followed, public companies hoarded cash. Howard Silverblatt at S&P reports that the payout ratio in 1936 of US public companies was 29%. Ironically, in our opinion, we are in the same kind of circumstance and have the same kind of payout ratios today. See our June 1st, 2011 missive called “Cash Hoards” to understand the history more fully. Click here for missive.

Last summer, Amgen was trading in the low $50’s on a per share basis and had never paid a dividend as a public company. Amgen declared their first ever cash dividend at $.28 quarterly last summer. Since then, they did a Dutch auction, buying back 9% of their shares and raised the dividend to $.36 per quarter. Amgen’s first ever dividend was a higher yield on share price than the 10-year Treasury bond yield! I have been in the investment business for 31 years and can’t ever remember an initial dividend offering more than the 10-year Treasury interest rate. We believe it is no coincidence that Amgen is trading above $64 per share on December 29, 2011. At the $1.44 annualized dividend rate, it yields around 2.23%, still significantly above the Treasury bond yield.

Amgen still has a payout ratio below 30% and has massive free-cash flow. They could be an aggressive dividend growth company going forward as we believe their balance sheet is strong and the future earnings look bright. Their newest product Denosumab is selling briskly in the form of Prolia for Osteoporosis and Xgeva for treating cancerous tumors. Management seems to have learned what scared investors want from a company.

At the end of June in 2011, EBay closed at $32.27 per share. We believe they have a fortress balance sheet. Their PayPal division is growing like weeds and throwing off massive free-cash flow. Their legacy Marketplace business has turned the corner and is growing nicely, while continuing to throw off over a billion dollars in free cash flow. EBay is buying back stock, but they don’t pay a dividend. The stock was trading between $30 and $31 per share in the last week of 2011. Investors can’t help but like the operating results of EBay’s management team, but they are too scared from the last 12 years of non-existent price appreciation to bet on it alone.

Silverblatt pointed out that the historical payout ratio over the last 50 years is 52.6% and over the last 20 years it was 46%. At Smead Capital Management, we believe that the companies which raise their dividend payout ratio towards the historical averages from the position of strong balance sheets, wide moats and relatively non-cyclical earnings performance will enjoy the kind of outsized price gains that Amgen has seen in the second half of 2011. Hopefully, EBay will get the memo.

Best Wishes,

William Smead

The information contained in this missive represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. Some of the securities identified and described in this missive are a sample of issuers being currently recommended for suitable clients as of the date of this missive and do not represent all of the securities purchased or recommended for our clients. It should not be assumed that investing in these securities was or will be profitable. A list of all recommendations made by Smead Capital Management with in the past twelve month period is available upon request.

We Advise Investors

Sign up to get our advice sent straight to your inbox.

Recent Missives

Late 2021 Speculation is Back

July 10, 2025

Our long-time investors are probably wondering why we haven't made any gains over the last 18 months. First, we have no ability to predict what already popular stocks will stay or get more...

⟶ Keep Reading

BNN Bloomberg: Cole Smead, CFA on Oil, Energy and Canadian Natural Gas

July 2, 2025

    LNG project has initial export capacity of 14M tons annually   For more information go to www.bnnbloomberg.ca. The information contained in this article represents SCM’s opinions, and should not […]

⟶ Keep Reading

Reuters: Cole Smead, CFA on the Current Market Rally

June 30, 2025

  S&P 500, Nasdaq close at record highs, cap best quarter in over a year By Sabrina Valle For more information go to reuters.com. The information contained in this tv […]

⟶ Keep Reading

Bloomberg: Cole Smead, CFA on Bank Stocks and Net Interest Margins

June 26, 2025

It’s ‘Game On’ for Bank Stocks as Rules Relax and Deals Rebound, Mayo Says By Georgie McKay For more information go to www.bloomberg.com. The information contained in this article represents […]

⟶ Keep Reading

Financial Post: Cole Smead, CFA on Aggressive Canadian Oil Companies

June 20, 2025

M&A in Canadian oil and gas accelerating: ‘We see a lot of consolidation’ says Keyera CEO Observers say a wave of consolidation is underway in the oilpatch By Meghan Potkins […]

⟶ Keep Reading

Bloomberg The Close: Cole Smead, CFA on Shock-Proof Oil Stocks 

June 20, 2025

Shock-Proof Oil Stocks to Weather the Geopolitical Storm By Romaine Bostick and Scarlet Fu For more information go to www.bloomberg.com. Stocks mentioned: SCR.TO The information contained in this article represents […]

⟶ Keep Reading

We Advise Investors

Sign up to get our advice sent straight to your inbox.

US INVESTORS

Individual Investors

OR

Financial Advisors, Family Offices,
and Institutional Investors

OR

NON-US INVESTORS

Individual Investors

OR

Financial Advisors, Family Offices,
and Institutional Investors

OR

Scroll to Top